Request Your Free eGuide Now:

"Assess HER2 Status in Solid Tumors to Inform Eligibility for Enhertu"

This core visual aid from AstraZeneca and Daiichi Sankyo describes the relevance and prevalence of HER2 positivity across metastatic solid tumors; provides detail on the nuances of ASCO-CAP scoring criteria guidelines, including sample requirements and staining interpretation; and outlines who, when, and how to test for HER2 positivity using IHC testing.
View full description >

Connect or Login with Email

Get Started

Welcome Back, ().
at

Has your work information changed?

Welcome
Please review the fields below for completeness and accuracy prior to submitting.

Welcome Back, ().
Has your work information changed?

Valid email address is required to fulfill your request.